Alcoholic Hepatitis – A Comprehensive Medical Guide

Overview

Alcoholic hepatitis (AH) is an inflammatory condition of the liver caused by excessive, chronic alcohol consumption. It ranges from mild, reversible inflammation to severe, life‑threatening disease that may progress to cirrhosis.

• Who it affects: Adults who drink heavily for many years, with the highest risk in men (≈ 2–3 × higher than women) but women develop severe disease after lower cumulative alcohol exposure.
• Prevalence: In the United States, alcoholic liver disease (ALD) accounts for ~30 % of all cirrhosis cases; of those, 10–20 % present with acute alcoholic hepatitis each year. Worldwide, WHO estimates > 2 billion people are current drinkers, and ~ 1 % of heavy drinkers develop AH annually.

Early recognition is critical because severe AH carries a 30‑day mortality of 20‑50 % and a 1‑year mortality exceeding 50 % if untreated.¹

Symptoms

Symptoms can be subtle in early disease and become more pronounced as inflammation worsens. Common manifestations include:

• Jaundice: Yellowing of the skin and sclera due to elevated bilirubin.
• Fever: Low‑grade (often 38‑39 °C) without an infectious source.
• Right upper‑quadrant (RUQ) abdominal pain or tenderness: Tenderness over the liver capsule.
• Fatigue & weakness: Generalized lack of energy.
• Loss of appetite and weight loss: May be accompanied by nausea.
• Enlarged liver (hepatomegaly): Palpable on physical exam.
• Ascites: Accumulation of fluid in the abdomen in advanced cases.
• Spider angiomas & palmar erythema: Vascular skin changes.
• Confusion or altered mental status (hepatic encephalopathy): Indicates severe liver dysfunction.
• Coagulopathy: Easy bruising or bleeding due to reduced clotting factors.

Causes and Risk Factors

Primary cause

Chronic excessive alcohol intake leads to toxic metabolites (acetaldehyde) that damage hepatocytes, trigger an inflammatory cascade, and promote fibrosis.

Key risk factors

• Quantity and duration of alcohol use: Typically > 60 g/day (≈ 4–5 drinks) for > 5 years. Women develop AH after ~30 g/day.
• Binge drinking patterns: Sharp spikes in blood alcohol level increase hepatic injury.
• Genetic predisposition: Polymorphisms in ADH1B, ALDH2, and PNPLA3 affect metabolism and susceptibility.
• Sex: Female hormones increase gut permeability and inflammatory response.
• Obesity & metabolic syndrome: Synergistic with alcohol to worsen steatosis.
• Viral hepatitis (HBV, HCV) or other liver diseases: Co‑infection accelerates damage.
• Smoking: Additional oxidative stress.
• Poor nutrition: Malnutrition, especially protein‑calorie deficiency, worsens outcomes.

Diagnosis

Diagnosing alcoholic hepatitis requires a combination of history, physical exam, laboratory tests, and imaging. No single test is definitive.

1. Clinical assessment

• Detailed alcohol use history (type, amount, pattern).
• Physical signs of chronic liver disease (spider angiomas, palmar erythema, ascites).

2. Laboratory tests

Test	Typical finding in AH
AST (aspartate aminotransferase)	Elevated, often > 50 U/L, AST/ALT ratio > 2
ALT (alanine aminotransferase)	Modestly elevated, usually < 300 U/L
Gamma‑glutamyl transferase (GGT)	Markedly raised
Bilirubin	Elevated (often > 5 mg/dL in severe disease)
Prothrombin time / INR	Prolonged, indicating impaired synthetic function
Complete blood count	Leukocytosis (infection must be ruled out)
Serum albumin	Low in chronic disease

3. Imaging

• Ultrasound: Shows fatty liver, hepatomegaly, and rule out biliary obstruction.
• CT or MRI: Helpful for assessing fibrosis, ruling out other masses, and detecting ascites.

4. Scoring systems (prognostic)

• Maddrey’s Discriminant Function (DF): DF ≥ 32 predicts severe disease.
• Model for End‑Stage Liver Disease (MELD): MELD ≥ 20 associated with high 90‑day mortality.
• Glasgow Alcoholic Hepatitis Score (GAHS): Scores ≥ 9 suggest poor prognosis.

5. Liver biopsy (optional)

Reserved for atypical presentations or when other liver diseases must be excluded. Histology shows ballooned hepatocytes, Mallory‑Denk bodies, and neutrophilic infiltration.

Treatment Options

Treatment aims to halt alcohol‑induced injury, reduce inflammation, support liver regeneration, and prevent complications.

1. Immediate Alcohol Abstinence

Complete cessation is the single most important intervention. Evidence shows that > 6 months of sobriety improves survival dramatically.²

2. Nutritional Support

• High‑protein, high‑calorie diet (30–35 kcal/kg/day).
• Enteral feeding (via nasogastric tube) if oral intake < 50 % of needs.
• Supplementation with thiamine (100 mg IV before glucose) to prevent Wernicke’s encephalopathy.
• Consider zinc (220 mg elemental zinc daily) and folate.

3. Pharmacologic Therapy

Medication	Indication	Key points
Corticosteroids (prednisone 40 mg PO daily or methylprednisolone 32 mg IV daily)	Severe AH (DF ≥ 32, MELD ≥ 20)	Improves 28‑day survival; monitor for infection; stop if Lille score > 0.45 after 7 days.
Pentoxifylline (400 mg PO TID)	Alternative when steroids contraindicated	Modest benefit; reduces risk of hepatorenal syndrome.
N-acetylcysteine (IV 150 mg/kg over 1 h, then 50 mg/kg over 4 h, then 100 mg/kg over 16 h)	Adjunct with steroids in early severe AH	Improves short‑term survival; safe profile.
Antibiotics (e.g., ceftriaxone) prophylaxis	High risk of infection or spontaneous bacterial peritonitis (SBP)	Start if neutrophil count > 10,000/µL or ascitic fluid PMN ≥ 250 cells/mm³.
Budesonide (9 mg PO daily) – under investigation	Potential steroid-sparing option	Limited data; not first‑line.

4. Management of Complications

• Ascites: Sodium restriction (< 2 g/day), diuretics (spironolactone + furosemide), therapeutic paracentesis if tense.
• Variceal bleeding: Endoscopic band ligation, non‑selective beta‑blockers (carvedilol, propranolol).
• Encephalopathy: Lactulose 25 mL PO q6h, rifaximin 550 mg PO BID if refractory.
• Hepatorenal syndrome: Albumin infusions, vasoconstrictors (terlipressin) and early transplant referral.

5. Liver Transplantation

For selected patients with severe AH who do not respond to medical therapy (e.g., Lille score > 0.45) and demonstrate commitment to abstinence, early transplantation can yield 5‑year survival > 80 %.³

Living with Alcoholic Hepatitis

Daily Management Tips

• Zero‑alcohol policy: Keep alcohol completely out of the home; consider support groups (AA, SMART Recovery).
• Nutrition: Eat small, frequent meals; include lean protein, complex carbs, and healthy fats; avoid raw seafood if cirrhosis is present.
• Hydration: Aim for 2–3 L of water daily unless fluid‑restricted.
• Medication adherence: Use a pill organizer; never stop steroids abruptly without physician guidance.
• Regular follow‑up: Labs (CBC, CMP, INR) every 1–2 weeks initially, then monthly.
• Vaccinations: Hepatitis A & B, pneumococcal, annual flu vaccine.
• Physical activity: Light walking 20–30 minutes most days improves muscle mass and mood.
• Monitor for signs of decompensation: New abdominal swelling, confusion, dark urine, or vomiting blood.

Prevention

Because alcohol is the root cause, prevention hinges on responsible drinking and early intervention.

• Follow drinking guidelines: ≤ 14 g/day for women, ≤ 28 g/day for men (≈ 1–2 standard drinks).
• Limit binge episodes: No more than 4 drinks (women) or 5 drinks (men) in a single occasion.
• Screening: Use AUDIT‑C or CAGE questionnaires during primary‑care visits; intervene early.
• Address co‑existing conditions: Treat obesity, diabetes, and viral hepatitis.
• Education: Public health campaigns highlighting the risk of chronic heavy drinking.

Complications

If untreated, alcoholic hepatitis can progress rapidly to irreversible liver damage and systemic complications:

• Cirrhosis: Permanent scarring; may lead to portal hypertension.
• Hepatic encephalopathy: Cognitive decline, coma.
• Ascites & spontaneous bacterial peritonitis (SBP).
• Variceal hemorrhage: Life‑threatening GI bleeding.
• Hepatorenal syndrome: Functional renal failure.
• Hepatocellular carcinoma (HCC): Increased risk even after abstinence.
• Coagulopathy & bleeding diathesis.
• Malnutrition and sarcopenia.

When to Seek Emergency Care

References

1. Mayo Clinic. Alcoholic Hepatitis. https://www.mayoclinic.org
2. Centers for Disease Control and Prevention. Alcohol Use and Your Health. https://www.cdc.gov
3. National Institutes of Health. Liver Transplantation for Alcoholic Hepatitis. https://www.nih.gov
4. Cleveland Clinic. Alcoholic Hepatitis Treatment Options. https://my.clevelandclinic.org
5. World Health Organization. Global Status Report on Alcohol and Health 2018. https://www.who.int